1 / 7

BeSt Study: Patient Characteristics

BeSt Study: Patient Characteristics. Total Population 508 Female 67% Male 33% Age (years) 54 Duration of symptoms (weeks) 23 Time diagnosis – inclusion (weeks) 2 DAS 44 4.4 RF-positive 65% With erosion 72% Sharp/vdHeijde score 4.

dyan
Télécharger la présentation

BeSt Study: Patient Characteristics

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. BeSt Study: Patient Characteristics Total Population 508 Female 67% Male 33% Age (years) 54 Duration of symptoms (weeks) 23 Time diagnosis – inclusion (weeks) 2 DAS 44 4.4 RF-positive 65% With erosion 72% Sharp/vdHeijde score 4 Adapted from Goekoop-Ruiterman et al. Arthritis Rheum 2005;52(11):3381-90.

  2. Remission Rates for Patients on Initial Methotrexate/Infliximab Treatment for Early RA Adapted from: 1. Allaart et al. Clin Exp Rheumatol 2006;24:S77-S82. 2. Van der Kooij et al. ACR 2006, abstract 658. 3. Van der Kooij et al. EULAR 2007, abstract THU0215. 4. Klarenbeek et al. EULAR 2008, abstract THU0162.

  3. DAS Results for Initial vs. Delayed Treatment with IFX + MTX at 2-year follow-up 100 P<0.001 80 56 60 Initial IFX + MTX (n=120) Delayed IFX+ MTX (n=86) P=0.005 40 28 25 18 15 20 5 0 % failed on IFX + MTX % stopped IFX and still DAS <2.4 % stopped IFX and still DAS <1.6 Delayed: Early RA patients started combination IFX + MTX therapy after failing DMARDs IFX = infliximab MTX = methotrexate Adapted from van der Kooij et al. EULAR 2007, abstract OP0010.

  4. Infliximab 3 mg/kg q 8 + MTX (N=10) 50 40 MTX alone (N=10) 30 20 10 0 0 2 6 14 22 30 38 46 54 62 78 104 = Infliximab/placebo infusions Comparative Reduction in CRP Levels 0 to 54 weeks CRP AUC (P<0.05) CRP (mg/dL) Infliximab-free period Weeks Adapted from Quinn et al. Arthritis Rheum 2005;52:27-35.

  5. BeSt Safety Results Adapted from Goedkoop-Ruiterman et al. Arthritis Rheum 2005;52:3381-90.

More Related